Regulatory Solutions

  1. Accelerate Drug Development With Innovative 360˚ CDMO And CRO Solutions 6/9/2026

    Accelerator™ Drug Development provides a strategic, end-to-end partnership model that helps sponsors optimize resources, overcome development challenges, and advance promising therapies.

  2. ICH E6(R3) Is Here: How Should You Handle It? 5/27/2026

    Prepare for ICH E6(R3) with integrated oversight, audit-ready data, and streamlined trial operations designed to reduce burden, accelerate timelines, and support compliance.

  3. Support For Efficient FDA Interactions 5/27/2026

    In today’s regulatory climate, ongoing discussion about FDA workload, funding constraints, and shifting review priorities have sparked anxiety across the biopharma industry — especially for sponsors preparing for key submissions like INDs or NDAs. At Veristat, our most recent interactions reflect continued responsiveness and constructive engagement from FDA.

  4. Data-Driven Paths To Rare/Ultra-Rare Disease Therapy Approval 5/22/2026

    Explore how integrated regulatory, statistical, and operational expertise can be applied to help sponsors navigate complex development pathways and accelerate global approvals.

  5. Human Abuse Potential: Selecting A Positive Control 5/8/2026

    Choosing an effective positive control in HAP studies is critical but not always straightforward. Learn how to justify comparator and dose selection.

  6. Human Abuse Potential: CSS Interactions 5/8/2026

    Learn how, by embedding FDA engagement into the development process, sponsors can strengthen their abuse potential assessment and support smoother regulatory review.

  7. Human Abuse Potential: Subjective Ratings 5/5/2026

    Accurate subjective ratings are central to Human Abuse Potential studies. Learn how Visual Analog Scales are administered, what influences responses, and why data collection practices are essential.

  8. cGMP Compliant Pharmacy 5/1/2026

    See how experienced compounding support helps ensure study drugs are prepared accurately and consistently across administration routes, meeting cGMP requirements while supporting clinical protocols.

  9. Human Abuse Potential: Pharmacy Considerations 5/1/2026

    Master the complexities of controlled substance handling, over-encapsulation, and dosing strategies to ensure the data integrity and regulatory compliance of abuse potential assessments.

  10. Develop Site-Centric Protocols To Optimize Enrollment 4/10/2026

    Optimize clinical trial protocols by aligning scientific goals with real-world site operations. Improve enrollment, reduce site burden, and minimize costly amendments through data-driven design.